Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,915 recruiting studies in this area right now.
By phase
- Not applicable2,022
- Phase 21,072
- Phase 1791
- Phase 1/Phase 2478
- Phase 3344
- Phase 4125
- Phase 2/Phase 383
Top conditions
- Multiple Myeloma327
- Acute Myeloid Leukemia280
- Lymphoma178
- Sickle Cell Disease133
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia95
- Follicular Lymphoma70
- Hematologic Malignancy67
- Myelodysplastic Syndrome64
- Hodgkin Lymphoma63
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm53
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center58
- Mayo Clinic55
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital44
- Peking University People's Hospital43
Where studies are running
- California396
- Texas185
- Alabama156
- Maryland152
- Arizona125
- Florida105
- Massachusetts102
- New York98
- Ohio70
- Minnesota69
Recruiting studies4,915 total
- NCT06733051RecruitingPhase 2
Study of Golidocitinib and Benmelstobart for relapsed ENKTL lymphoma
This trial tests a new drug combination for people with a rare type of lymphoma (ENKTL) that has come back or not responded after prior treatment. It aims to see if the combination can help control the disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07416604RecruitingPhase 3
Study of NXT007 vs emicizumab for hemophilia A
This trial tests if a new medicine, NXT007, is better than emicizumab at preventing bleeding episodes in people with hemophilia A. It may be an option for those with or without inhibitors who are willing to switch to a preventive treatment.
Orange, CaliforniaAges 12 years+ - NCT07416526RecruitingPhase 3
Testing NXT007 for hemophilia A without inhibitors
This study tests a new medicine called NXT007 for people with hemophilia A. It compares NXT007 to standard factor VIII treatment to see if it works better at preventing bleeding episodes.
Aurora, ColoradoAges 12 years+ - NCT07422610RecruitingPhase 1
Study of Pelabresib for advanced cancer with liver issues
This trial tests how the drug pelabresib works in people with advanced cancer who also have mild to severe liver problems. It aims to understand safety and how the drug moves through the body.
BordeauxAges 18–75 - NCT06816056Recruiting
Foot therapy for hemophilia ankle arthritis
This study tests if manual therapy can help patients with hemophilia who have arthritis in their ankle. It seeks to improve joint health and reduce pain.
MurciaAges 18–65 - NCT07416890RecruitingPhase 2
Study of thiotepa, pirtobrutinib, and sintilimab for CNS lymphoma
This trial tests a combination of three drugs for people with central nervous system (CNS) lymphoma that has come back or not responded to treatment, or for those who cannot take standard chemotherapy. The goal is to see if this new combination is safe and effective.
Hangzhou, ZhejiangAges 18–80 - NCT07424157Recruiting
Long-term gene therapy follow-up study
This study follows patients who received gene therapy at Seattle Children's Hospital to check on their health and safety over time. It helps doctors understand how well the treatment works in the long run.
Seattle, WashingtonAges Any age - NCT07418827Recruiting
Growing up with severe hemophilia: A follow-up study
This study follows up with young adults who have severe hemophilia to learn about their health and life as they grow into adulthood. It aims to understand the challenges they face and what helps them thrive.
Saint-Denis, La RéunionAges 20–29 - NCT07418190RecruitingPhase 2
Combination therapy for relapsed follicular lymphoma
This trial tests a combination of three targeted drugs (zanubrutinib, rituximab, lenalidomide) plus an immunotherapy drug (tislelizumab) for people with follicular lymphoma that has returned or not responded to at least two prior treatments. The goal is to see if this combination is safe and effective.
Nanjing, JiangsuAges 18–75 - NCT07420959RecruitingPhase 1/Phase 2
ABBV-383 for Waldenström macroglobulinemia that came back
This trial tests a new drug called ABBV-383 for people with Waldenström macroglobulinemia that has returned or stopped responding to treatment. The drug is given as an infusion and aims to attack the cancer cells. This might help if you've already tried a BTK inhibitor.
Rochester, MinnesotaAges 18 years+ - NCT07424222RecruitingPhase 1
Ruxolitinib for a serious immune reaction after CAR T therapy
This trial tests a drug called ruxolitinib for a rare but serious condition called IEC-HS that can happen after CAR T cell treatment. The goal is to see if ruxolitinib can calm this overactive immune response.
Baltimore, MarylandAges 18–99 - NCT07416682RecruitingEarly Phase 1
CAR-T cell therapy for high-risk plasma cell cancers
This trial tests a new immune cell therapy (CAR-T) that targets two markers on high-risk plasma cell cancers. It aims to see if this treatment is safe and helpful for people with aggressive or resistant forms of this disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT07422337Recruiting
Vaccine protection after blinatumomab for childhood leukemia
This study checks how well vaccines you got as a baby still protect you after treatment with blinatumomab for B-cell leukemia or lymphoma. It helps doctors understand if you may need extra vaccines.
Little Rock, ArkansasAges 1–23 - NCT07418099Recruiting
Study on a blood test for prolonged clotting time
This study looks at a special blood test (clot waveform analysis) to see if it can help doctors better understand why some people have a prolonged clotting time. This might help them find the cause more quickly and accurately.
Leganés, MadridAges Any age - NCT07420790Recruiting
Comparing two treatments for older AML patients before transplant
This trial looks back at how older adults with acute myeloid leukemia (AML) did when treated with either standard chemotherapy or a newer combination of venetoclax and decitabine, before a stem cell transplant. The goal is to see which treatment may lead to better outcomes.
Brescia, ItalyAges 18–75 - NCT07419178Recruiting
New scan test for scarring in blood cancers
This study tests a new way to detect scar tissue in the bone marrow using a special scan and blood test. It might help doctors see how your disease is changing without needing a bone marrow biopsy.
Parma, ItalyAges 18 years+ - NCT06196203RecruitingPhase 2
Study of AK117 with Azacitidine for High-Risk MDS
This trial tests a new drug, AK117, combined with azacitidine for people newly diagnosed with high-risk myelodysplastic syndromes (MDS), a blood disorder. The goal is to see if the combination can help improve outcomes.
Los Angeles, CaliforniaAges 18 years+ - NCT06271512Recruiting
Follow-up study for beta-thalassemia patients treated with beti-cel
This study is for people with beta-thalassemia who have already received the gene therapy betibeglogene autotemcel (beti-cel). It collects information to learn how patients are doing after this treatment in real-world settings.
Oakland, CaliforniaAges Any age - NCT06791681RecruitingEarly Phase 1
ESO-T01 for returning or hard-to-treat multiple myeloma
This trial tests a new treatment called ESO-T01 for people with multiple myeloma that has come back or is not responding to at least two prior therapies. It aims to see if this therapy is safe and can help control the disease.
Wuhan, HubeiAges 18 years+ - NCT07413809RecruitingPhase 3
Preventing nausea after stem cell transplant: olanzapine vs dexamethasone
This trial compares two anti-nausea drug regimens (one with olanzapine, one with dexamethasone) to prevent delayed nausea and vomiting after a stem cell transplant for multiple myeloma. It aims to find which is better at controlling these side effects.
Ningbo, ZhejiangAges 18–65 - NCT07409428RecruitingPhase 3
Study of HMPL-760 plus R-GemOx for relapsed or refractory DLBCL
This trial tests an experimental drug called HMPL-760 combined with a standard chemo-immunotherapy regimen (R-GemOx) for people whose diffuse large B-cell lymphoma (DLBCL) has come back or stopped responding to treatment. The goal is to see if adding HMPL-760 works better than the standard approach alone.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07409246RecruitingPhase 1
Study of ABBV-438 for multiple myeloma patients
This trial tests a new intravenous treatment, ABBV-438, for adults with multiple myeloma that has returned or not responded to prior therapies. It aims to see if the drug is safe, tolerable, and how it moves through the body.
Duarte, CaliforniaAges 18 years+ - NCT07416162Recruiting
Study of iptacopan for PNH or C3G in Korea
This trial tests a medicine called iptacopan for people with paroxysmal nocturnal hemoglobinuria (a rare blood disorder) or C3 glomerulopathy (a kidney disease). It aims to see if the drug is safe and effective for Korean patients.
JeollanamAges 18–99 - NCT07410520RecruitingPhase 2
New drug combo for brain lymphoma
This trial tests a combination of three drugs (rituximab, methotrexate, and orelabrutinib) plus a PD-1 inhibitor for newly diagnosed or relapsed central nervous system lymphoma. The goal is to see if this new combination can improve outcomes for patients with this rare type of lymphoma.
Nanjing, JiangsuAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,915 recruiting hematology studies from the U.S. registry right now, out of 7,288 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.